Human Papillomavirus News and Research RSS Feed - Human Papillomavirus News and Research

9-Valent HPV vaccine can potentially prevent 80% of cervical cancers in the U.S.

9-Valent HPV vaccine can potentially prevent 80% of cervical cancers in the U.S.

The new 9-valent human papillomavirus vaccine, can potentially prevent 80 percent of cervical cancers in the United States, if given to all 11- or 12-year-old children before they are exposed to the virus. [More]
New study finds that electronic reminders help raise HPV vaccination rates

New study finds that electronic reminders help raise HPV vaccination rates

A new study finds that a simple reminder via electronic health record systems may go a long way in encouraging patients to get the HPV vaccine that protects against cervical cancer. The HPV vaccine has the lowest completion rates of any other vaccine. [More]
Scientists identify key factors in parents' decision-making about HPV vaccination of daughters

Scientists identify key factors in parents' decision-making about HPV vaccination of daughters

Human Papillomavirus (HPV) is a leading cause of sexually transmitted diseases, with more than 70% of sexually active people getting the virus at least once in their lifetimes. Persistent infection with some HPV strains can lead to cervical cancer, the second most common cancer in women, as well as to head-and-neck and other types of cancer and anogenital warts in both men and women. [More]
Texas Biomed scientists awarded NIH grant to develop potential HPV-based HIV vaccine

Texas Biomed scientists awarded NIH grant to develop potential HPV-based HIV vaccine

Scientists at Texas Biomedical Research Institute have begun work on a nearly $3.4 million study funded by the National Institutes of Health over the next four years to create an attenuated, or weakened, virus that is a hybrid of the papilloma virus and the human immunodeficiency virus, with the potential to jumpstart a body's immune response to develop antibodies against both viruses. [More]
Men undergoing circumcision may be at increased risk of infecting female partners with HIV

Men undergoing circumcision may be at increased risk of infecting female partners with HIV

In the midst of an international campaign to slow the spread of HIV in sub-Saharan Africa, the World Health Organization recommends male circumcision (the surgical removal of foreskin from the penis) which reduces HIV acquisition by 50-60%. [More]
Oral, Head & Neck Cancer Awareness Week: Mount Sinai experts to share tips on cancer prevention

Oral, Head & Neck Cancer Awareness Week: Mount Sinai experts to share tips on cancer prevention

Mouth and throat cancers are the fastest rising cancers today. They account for over 40,000 cases per year in the U.S. The American Cancer Society estimates that there will be 121,790 new cases of head and neck cancer diagnosed in 2015 and 14,240 deaths. These numbers include tongue cancer, throat cancers caused by the human papillomavirus or HPV, voice box cancer, melanoma of the face and thyroid cancers. [More]
HPV may cause oropharyngeal cancer

HPV may cause oropharyngeal cancer

Tobacco and alcohol use may be the most common cause of head and neck cancers, but a new culprit has come on the scene in recent years. [More]
Dental experts join Oral Cancer Foundation to raise awareness about oral cancer

Dental experts join Oral Cancer Foundation to raise awareness about oral cancer

When oral and oropharyngeal cancers (cancers of the mouth and upper throat) are detected and treated early in their development, survival rates can improve significantly. Regular oral cancer examinations performed by your oral health professional remain the best method for detecting oral cancer in its early stages. [More]
Merck announces availability of GARDASIL 9 HPV vaccine in Canada

Merck announces availability of GARDASIL 9 HPV vaccine in Canada

Merck, known as MSD outside the United States and Canada, announced today that GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), Merck's 9-valent human papillomavirus (HPV) vaccine, is now available in Canada. [More]
MED15 may serve as prognostic marker for HNSCC recurrence

MED15 may serve as prognostic marker for HNSCC recurrence

A new study provides the first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC). MED15 overexpression was found to be associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors, according to the study published in The American Journal of Pathology. [More]
Duke study proposes strategy to protect more people from HPV using limited public funds

Duke study proposes strategy to protect more people from HPV using limited public funds

A Duke University study proposes a strategy to better use limited public health care dollars for protecting more people from a sexually transmitted infection called human papillomavirus (HPV) and the cancers it can cause. [More]
Medical Diagnostic Laboratories now offers new HPV tests

Medical Diagnostic Laboratories now offers new HPV tests

Medical Diagnostic Laboratories, L.L.C., a CLIA-certified, CAP-accredited laboratory which specializes in high complexity, state-of-the-art, automated DNA-based molecular analyses, announces that it is now offering new Human Papillomavirus (HPV) testing which utilizes cutting edge technology, including next- generation DNA sequencing platforms. [More]
New HPV vaccine has potential to prevent 90% of conditions triggered by HPV

New HPV vaccine has potential to prevent 90% of conditions triggered by HPV

A new vaccine against HPV infections has the potential to prevent 90 per cent of all of the conditions triggered by the human papillomavirus. These are the findings of a randomised, controlled, international study involving a new, 9-component vaccine against HPV used on more than 14,000 young women aged between 16 and 26 years. [More]
International phase 2/3 trial shows Gardasil 9 vaccine protects against nine HPV types

International phase 2/3 trial shows Gardasil 9 vaccine protects against nine HPV types

Approximately 12,000 women are diagnosed with cervical cancer each year in the United States and another 4,000 die annually from the disease. However, most cervical cancers are preventable through immunization against the human papillomavirus (HPV). A pivotal international phase 2/3 clinical trial involving Moffitt Cancer Center faculty demonstrated that vaccination with Gardasil 9 protects against nine HPV types, seven of which cause most cases of cervical, vulvar, and vaginal disease. [More]
New nine-valent HPV vaccine has potential to dramatically reduce cervical cancer rates

New nine-valent HPV vaccine has potential to dramatically reduce cervical cancer rates

A multinational study on a diverse group of women shows that a new nine-valent human papillomavirus (HPV) vaccine prevents infections and disease associated with the vaccine types, according to a paper published today in The New England Journal of Medicine. [More]
HPV vaccination does not affect sexual behaviours

HPV vaccination does not affect sexual behaviours

Research has shown that human papillomavirus (HPV) vaccination is not associated with increases in sexually transmitted infections (STIs). [More]
HPV vaccine does not increase rates of STIs in adolescent females

HPV vaccine does not increase rates of STIs in adolescent females

Receiving the human papillomavirus vaccine does not increase rates of sexually transmitted infections (STIs) in adolescent females. The vaccine, which can prevent cervical cancer in women, has had a low uptake, partly because of concerns about how it will affect adolescent sexual activity. [More]
New model proposed for predicting outcomes more accurately in HPV-related throat cancer patients

New model proposed for predicting outcomes more accurately in HPV-related throat cancer patients

Researchers at the Princess Margaret Cancer Centre are proposing a new model to enable doctors to predict outcomes more accurately for patients with throat cancers specifically caused by Human Papillomavirus (HPV). [More]
TOSH Program aims to improve oral-systemic health

TOSH Program aims to improve oral-systemic health

Improving oral health is a leading population health goal; however, curricula preparing health professionals have a dearth of oral health content and clinical experiences. Funded by a grant from the Health Resources and Service Administration, New York University College of Nursing's Teaching Oral-Systemic Health Program is working to build interprofessional oral health workforce capacity which addresses a significant public health issue, increases oral health care access, and improves oral-systemic health across the lifespan. [More]
UTMB study reveals that only about half of teenage girls get HPV vaccine at the recommended age

UTMB study reveals that only about half of teenage girls get HPV vaccine at the recommended age

It's a virus that is responsible for almost all cases of cervical cancer but a new study by University of Texas Medical Branch at Galveston researchers indicates that only about half of the girls receive the vaccine at the recommended age to best protect themselves. [More]
Advertisement
Advertisement